AdAlta Ltd (ASX: 1AD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AdAlta Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$11.37 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
631.46 million
Earnings per share
-0.011
Dividend per share
N/A
Year To Date Return
-33.33%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AdAlta Ltd (ASX: 1AD)
Latest News
Consumer Staples & Discretionary Shares
Up 19% in 2024, is it time to buy or sell Coles shares?
Share Market News
AdAlta (ASX:1AD) share price rockets 31% on United States FDA update
1AD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About AdAlta Ltd
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
1AD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 Jan 2025 | $0.02 | $0.00 | 0.00% | 627,911 | $0.02 | $0.02 | $0.02 |
| 30 Dec 2024 | $0.02 | $0.00 | 0.00% | 737 | $0.02 | $0.02 | $0.02 |
| 23 Dec 2024 | $0.02 | $0.00 | 0.00% | 512,960 | $0.02 | $0.02 | $0.01 |
| 19 Dec 2024 | $0.02 | $0.00 | 0.00% | 503,220 | $0.02 | $0.02 | $0.02 |
| 18 Dec 2024 | $0.02 | $0.00 | 0.00% | 382,434 | $0.02 | $0.02 | $0.02 |
| 17 Dec 2024 | $0.02 | $0.00 | 0.00% | 46,587 | $0.02 | $0.02 | $0.02 |
| 16 Dec 2024 | $0.02 | $0.00 | 0.00% | 558,158 | $0.02 | $0.02 | $0.02 |
| 13 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,764,071 | $0.02 | $0.02 | $0.02 |
| 12 Dec 2024 | $0.02 | $0.00 | 0.00% | 89,797 | $0.02 | $0.02 | $0.02 |
| 10 Dec 2024 | $0.02 | $0.00 | 0.00% | 721,016 | $0.02 | $0.02 | $0.02 |
| 09 Dec 2024 | $0.02 | $0.00 | 0.00% | 328 | $0.02 | $0.02 | $0.02 |
| 06 Dec 2024 | $0.02 | $0.00 | 0.00% | 141,705 | $0.02 | $0.02 | $0.02 |
| 03 Dec 2024 | $0.02 | $0.00 | 0.00% | 88,719 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Dec 2024 | Timothy Oldham | Issued | 757,195 | $13,629 |
Issue of securities.
|
| 04 Dec 2024 | Timothy Oldham | Issued | 1,396,999 | $25,145 |
Issue of securities. 1,396,999 performance rights
|
| 06 Sep 2024 | Timothy Oldham | Buy | 100,000 | $2,195 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Fuller | Non-Executive Director | Jul 2020 |
Dr Fuller has over 30 years of experience in pre-clinical, clinical development, medical and regulatory affairs with specialisations in early phase development and oncology.
|
| Dr Paul MacLeman | Non-Executive ChairmanNon-Executive Director | Oct 2019 |
Dr MacLeman has expertise in capital management, business development, technology commercialisation and sales & marketing globally.
|
| Mr Iain Ross | Non-Executive Director | Nov 2024 |
Mr Ross, has more than four decades of experience in the international life sciences and technology industries and has previously held roles in a array of multi-national companies such as Sandoz, Hoffman La Roche, Reed Business Publishing, and Celltech Group. He has completed multiple financing transactions and has more than 30 years of experience in cross-border management as Chairman and CEO, including substantial knowledge of international capital markets and structuring for growth . Mr Ross has led and participated in eight Initial Public Offerings (IPOs) and has direct experience in merger and acquisition (M&A) transactions in Europe, the US, and the Pacific Rim. Currently, he serves as Chairman of both NASDAQ-listed Silence Therapeutics (NASDAQ:SLN) and ReNeuron Group plc. In addition, he is a Non Executive Director of Tern plc, a technology investment business listed on the Alternative Investment Market (AIM) in London, and FivepHusion Limited, a private oncology business based in Sydney. Iain is a shareholder in AdAlta.
|
| Dr Timothy Oldham | Managing DirectorChief Executive Officer | Oct 2019 |
Dr Oldham has more than 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products.
|
| Ms Michelle Burke | Non-Executive Director | Nov 2024 |
Ms Burke possesses expertise in cell therapies, strategy, and governance. Over time, she has held Non-Executive Director and Chair positions across diverse healthcare institutions. She is currently a Nonexecutive Director of Cell Therapies Pty Ltd, an Australian-based, globally active commercial contract development and manufacturing company specialising in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products. Ms Burke is also presently a Non-Executive Director for the Olivia Newton-John Cancer Research Institute and is a past Chair and Non-Executive Director of AusBiotech, the peak industry body for life sciences in Australia. Her former roles include senior commercial and corporate affairs positions at global healthcare companies Bristol Myers Squibb and SmithKline Beecham (now GSK). She is a member of the Pharmaceutical Benefits Advisory Committee and acts as a consultant to companies, governments, and academia on commercialisation, business planning, and policy in the healthcare industry.
|
| Mr Cameron Jones | Chief Financial OfficerCompany Secretary | May 2017 |
-
|
| Cameron Jones | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Sacavic Pty Ltd <Morris Super Fund A/C> | 97,441,722 | 16.36% |
| HSBC Custody Nominees (Australia) Limited | 85,720,663 | 14.39% |
| Fletcher Meurs Investments Pty Ltd | 27,029,924 | 4.54% |
| YCLP Pty Ltd <Yclp A/C> | 27,029,924 | 4.54% |
| Radiata Foundation Ltd | 20,560,519 | 3.45% |
| Meurs Holdings Pty Ltd <P&M Meurs Superannuation A/C> | 20,123,655 | 3.38% |
| Skiptan Pty Ltd <P&M Meurs Family A/C> | 19,407,256 | 3.26% |
| Mr Tzu Hsuan Tseng | 9,893,171 | 1.66% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 7,058,296 | 1.19% |
| Mr Craig Graeme Chapman <Nampac Discretionary A/C> | 5,000,000 | 0.84% |
| Scintilla Strategic Investments Limited | 5,000,000 | 0.84% |
| Mr John Okroglic | 4,693,397 | 0.79% |
| Citycastle Pty Ltd | 4,302,320 | 0.72% |
| Azzurra Investments Pty Ltd | 4,050,000 | 0.68% |
| Mr Kevin John Cairns & Mrs Catherine Valerie Cairns <Cairns Family Super A/C> | 4,000,000 | 0.67% |
| Mr Alistair David Strong | 4,000,000 | 0.67% |
| Mr David John Robinson | 3,833,000 | 0.64% |
| Mrs Gwen Murray Pfleger <Pfleger Family A/C> | 3,600,000 | 0.60% |
| Mr Peera Maytha | 3,600,000 | 0.60% |
| Castle Manor Pty Ltd <Arrendene Holdings A/C> | 3,503,904 | 0.59% |
| Huon Pine Pty Ltd <Huon Pine Investment A/C> | 3,250,000 | 0.55% |
| La Trobe University | 3,041,330 | 0.51% |
| Mr Michael Peter Hetrelezis <Mike'S Investment A/C> | 3,000,000 | 0.50% |
| Mr Kalpesh Varsani & Mrs Rita Varsani <Varsani Family S/F A/C> | 3,000,000 | 0.50% |
| Andrew P O'Brien Holdings Pty Ltd <Andrew P O'Brien A/C> | 2,944,445 | 0.49% |
